ADVB (Advanced Biomed) ROC (Joel Greenblatt) %: -264.15% (As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.07
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed ROC (Joel Greenblatt) %?

Advanced Biomed ADVB +3.10% 12 ROC (Joel Greenblatt) % is -264.15% as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 211 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 87.2% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Advanced Biomed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -264.15%.

The historical rank and industry rank for Advanced Biomed's ROC (Joel Greenblatt) % or its related term are showing as below:

ADVB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -603.16   Med: -281.74   Max: -200.33
Current: -603.16

During the past 5 years, Advanced Biomed's highest ROC (Joel Greenblatt) % was -200.33%. The lowest was -603.16%. And the median was -281.74%.

ADVB's ROC (Joel Greenblatt) % is ranked worse than
87.2% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02 vs ADVB: -603.16

Advanced Biomed's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Advanced Biomed  (NAS:ADVB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Advanced Biomed ROC (Joel Greenblatt) % Related Terms


Advanced Biomed ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed ROC (Joel Greenblatt) % Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
-200.33 -221.56 -281.74 -316.76 -553.30

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -385.74 -1,593.45 -547.97 -275.46 -264.15

ADVB vs MBAI, XWEL, NDRA: ROC (Joel Greenblatt) % Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Biomed ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's ROC (Joel Greenblatt) % falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.009 + 1.936) - (1.234 + 0 + 0)
=0.711

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.009 + 1.932) - (1.407 + 0 + 0)
=0.534

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Advanced Biomed for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.956/( ( (0.118 + max(0.711, 0)) + (0.118 + max(0.534, 0)) )/ 2 )
=-1.956/( ( 0.829 + 0.652 )/ 2 )
=-1.956/0.7405
=-264.15 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -264.15% mean?
Advanced Biomed (ADVB) has a ROC (Joel Greenblatt) % of -264.15% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #184 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 87.2%.
Is Advanced Biomed's ROC (Joel Greenblatt) % too high?
Advanced Biomed's current ROC (Joel Greenblatt) % is -264.15%. Based on the distribution chart, Advanced Biomed ranks #184 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's ROC (Joel Greenblatt) % compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #184 out of 211 companies for ROC (Joel Greenblatt) %. This places Advanced Biomed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current ROC (Joel Greenblatt) % is -264.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current ROC (Joel Greenblatt) % of -264.15%. The current ROC (Joel Greenblatt) % is -264.15%. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current ROC (Joel Greenblatt) % is -264.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price